Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orlistat

REVIVE

Empros Pharma AB · Phase 2 · Terminated · Enrollment 128

NCT01351753

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Metforminn/rn/rn/rn/r
Metformin + Orlistatn/rn/rn/rn/r
Metformin + Topiramaten/rn/rn/rn/r
Topiramaten/rn/rn/rn/r
Metformin + Topiramate + Orlistatn/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Metformin: endpoint not reported
  • Metformin + Orlistat: endpoint not reported
  • Metformin + Topiramate: endpoint not reported
  • Topiramate: endpoint not reported
  • Metformin + Topiramate + Orlistat: endpoint not reported
  • Placebo: endpoint not reported